AFP
FATE icon

Ausdal Financial Partners’s Fate Therapeutics FATE Stock Holding History

Ausdal Financial Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,007
Closed -$32.8K – 525
2024
Q2 		$32.8K Buy
+10,007
New +$43.8K ﹤0.01% 489

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Ausdal Financial Partners's FATE Position: Q3 2024 in Review

Ausdal Financial Partners sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 10,007 shares — an estimated $32.8K sold.

Ausdal Financial Partners first reported a position in FATE in Q2 2024 and held it in 1 quarter. The position peaked at $32.8K in Q2 2024. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Ausdal Financial Partners reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ausdal Financial Partners sold 10,007 Fate Therapeutics shares in Q3 2024, an estimated $32.8K.
  • Ausdal Financial Partners first reported a position in Fate Therapeutics in Q2 2024 and held it in 1 quarter.
  • Ausdal Financial Partners's Fate Therapeutics position peaked at $32.8K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Ausdal Financial Partners's 13F filing for Q3 2024, filed 4 Oct 2024.